CTOR
CITIUS ONCOLOGY, INC.Company Information
- Company Name
- CITIUS ONCOLOGY, INC.
- CIK
- CIK0001851484
- Category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Ticker: Exchange
- CTOR: Nasdaq
- Fiscal Year End
- September 30
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- CTOR
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- —
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 14,123,622
- Shares outstanding
- 107,890,452
- Ownership
- 13.09%
Earnings Market Reaction
- Filing date
- 2026-08-14
- Price on filing date
- —
- 1-month reaction
- -5.49%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Related Party | 2 | -3 | 11 | 10 | 3 | 2 | 3 | 1 | - | - | - | - | ||||||
Assets | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 17 | 3 | 7 | 4 | 0 | 0 | 0 | 0 | - | - | - | - | ||||||
| Cash | - | - | - | 4 | - | - | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Accounts Receivable Net Current | 1 | 1 | 4 | - | - | - | - | - | - | - | - | - | ||||||
| Inventory Net | 23 | 23 | 23 | 22 | 17 | 15 | 14 | 8 | - | - | - | - | ||||||
| Prepaid Expense Current | 3 | 3 | 3 | 1 | 1 | 3 | 3 | 3 | 0 | 0 | 0 | 0 | ||||||
| Assets Current | 43 | 29 | 37 | 28 | 18 | 18 | 17 | 11 | 0 | 0 | 0 | 0 | ||||||
Other Assets | ||||||||||||||||||
| Long Term Investments | - | - | - | - | - | - | - | - | 49 | 49 | 73 | 71 | ||||||
| Deferred Costs | - | 0 | - | - | - | - | - | - | - | - | - | - | ||||||
| Other Assets | - | 71 | 73 | 73 | 73 | 73 | 73 | 73 | - | - | - | - | ||||||
| Assets | 112 | 101 | 110 | 101 | 92 | 91 | 90 | 84 | 49 | 49 | 73 | 71 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 7 | 9 | 10 | 13 | 9 | 8 | 6 | 4 | - | - | - | - | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Accrued Liabilities Current | 26 | 24 | 5 | 4 | 8 | 9 | 6 | - | 0 | 0 | 0 | 0 | ||||||
| Notes Payable Current | - | - | - | - | - | - | - | - | 2 | 2 | - | - | ||||||
| Liabilities Current | 59 | 59 | 45 | 49 | 53 | 50 | 43 | 33 | 3 | 3 | 2 | 1 | ||||||
| Temporary Equity Carrying Amount Attributable To Parent | - | - | - | - | - | - | - | - | 49 | 48 | 73 | 71 | ||||||
| Finance Lease Liability Noncurrent | 6 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Deferred Income Tax Liabilities Net | 3 | 3 | 3 | 3 | 3 | 2 | 2 | 2 | - | - | - | - | ||||||
| Liabilities | 72 | 65 | 52 | 56 | 59 | 56 | 49 | 38 | - | - | - | - | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 145 | 131 | 128 | 109 | 91 | 89 | 87 | 85 | - | - | - | - | ||||||
| Retained Earnings Accumulated Deficit | -105 | -96 | -70 | -64 | -59 | -54 | -46 | -39 | -3 | -2 | -2 | -1 | ||||||
| Stockholders Equity | 40 | 35 | 58 | 45 | 32 | 36 | 41 | 46 | 17 | 20 | -2 | -1 | ||||||
| Temporary Equity Par Or Stated Value Per Share | - | - | - | - | - | - | - | - | 11.35 | 11.20 | 10.99 | 10.70 | ||||||
| Liabilities And Stockholders Equity | 112 | 101 | 110 | 101 | 92 | 91 | 90 | 84 | 49 | 49 | 73 | 71 | ||||||
| Shares Subject To Mandatory Redemption Settlement Terms Number Of Shares | - | - | - | - | - | - | - | - | 4 | 4 | 7 | 7 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 1 | 1 | 1 | 1 | ||||||
| Preferred Stock Shares Issued | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 400 | 400 | 400 | 400 | 400 | 100 | 100 | 100 | 110 | 150 | 150 | 150 | ||||||
| Common Stock Shares Issued | 106 | 93 | 85 | 84 | 72 | 72 | 72 | 72 | 2 | 2 | 2 | 2 | ||||||
| Shares Outstanding | 106 | 93 | 85 | 84 | 72 | 72 | 72 | 72 | 2 | 2 | 2 | 2 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialCITIUS ONCOLOGY, INC. (CTOR) — SEC Financial Statements & Analysis
CITIUS ONCOLOGY, INC. (CTOR) is a pharmaceutical preparations company, incorporated in DE. CITIUS ONCOLOGY, INC. trades on Nasdaq as: CTOR. CITIUS ONCOLOGY, INC. (CTOR)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14. Based on that filing, CITIUS ONCOLOGY, INC. carries a market cap of $70.13M, a P/E ratio of -1.71x, a P/B ratio of 1.74x, a P/S ratio of 9.87x, an enterprise value of $59.98M, and an EV/EBITDA multiple of -1.41x. On profitability, it posts an operating margin of -599.32%, a net margin of -577.99%, a Return on Equity (ROE) of -112.85%, a Return on Assets (ROA) of -40.30%, and a Return on Invested Capital (ROIC) of -135.43%. Per share, it reports EPS of $-0.38, diluted EPS of $-0.38, free cash flow per share of $-0.19, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 107.78% year-over-year and EPS growth of 37.80% year-over-year. On the balance sheet, it maintains a current ratio of 0.73x, a quick ratio of 0.29x, working capital of $-16.08M, a debt-to-equity ratio of 1.78x, a debt ratio of 0.64, an interest coverage ratio of -137.10x, free cash flow of $-20.90M (TTM), and net debt of $-10.15M. Figures sourced from SEC EDGAR.
- Market Cap
- $70.13M
- P/E TTM
- -1.71x
- EPS TTM
- $-0.38
- P/B TTM
- 1.74x
- ROE TTM
- -112.85%
- ROA TTM
- -40.30%
- Debt To Equity
- 1.78x
- Free Cash Flow TTM
- $-20.90M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is CITIUS ONCOLOGY, INC. in?
CITIUS ONCOLOGY, INC. (CTOR) operates in the Pharmaceutical Preparations industry.
What exchange does CTOR trade on?
CITIUS ONCOLOGY, INC. (CTOR) trades on the Nasdaq.
Where is CITIUS ONCOLOGY, INC. incorporated?
CITIUS ONCOLOGY, INC. is incorporated in DE.
When was CITIUS ONCOLOGY, INC. (CTOR)'s most recent SEC filing?
CITIUS ONCOLOGY, INC. (CTOR)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14.
What is CTOR's market cap?
CITIUS ONCOLOGY, INC. (CTOR) has a market capitalization of $70.13M as of 2026-06-30.
What is CTOR's EPS (earnings per share)?
CITIUS ONCOLOGY, INC. (CTOR)'s trailing twelve month EPS is $-0.38 as of 2026-06-30.
What is CTOR's ROE (return on equity)?
CITIUS ONCOLOGY, INC. (CTOR)'s trailing twelve month Return on Equity (ROE) is -112.85% as of 2026-06-30.
What is CTOR's ROA (return on assets)?
CITIUS ONCOLOGY, INC. (CTOR)'s trailing twelve month Return on Assets (ROA) is -40.30% as of 2026-06-30.
What is CTOR's ROIC (return on invested capital)?
CITIUS ONCOLOGY, INC. (CTOR)'s trailing twelve month Return on Invested Capital (ROIC) is -135.43% as of 2026-06-30.
What is CTOR's EV/EBITDA?
CITIUS ONCOLOGY, INC. (CTOR)'s trailing twelve month EV/EBITDA is -1.41x as of 2026-06-30.